Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. With the recent approval of another non-stimulant ADHD medication (viloxazine, brand name Qelbree), this is a good time to revisit atomoxetine. How effective is it? What are some of its pros and cons? This podcast will clarify the position of atomoxetine in our toolbox for treating children and adolescents with ADHD.
Joshua Feder, M.D.
Dr. Feder's Blog